

PROVINCIAL FUNDING SUMMARY

Ceritinib (Zykadia) for Metastatic Non-Small Cell Lung Cancer (pCODR 10062)

pERC Recommendation: Does Not Recommend

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 18, 2015

This information is current as of November 9, 2018.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	See Resubmission		
AB	See Resubmission		
SK	See Resubmission		
MB	See Resubmission		
ON	Not funded		
NS	See Resubmission		
NB	Not funded		
NL	Not funded		
PEI	Not funded		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.